It can be added to a gel for use with Mesotherapy or other aesthetic devices
Poster Session I - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.02 - SECONDARY PREVENTION P392 - ESOC25-2475 UNLOCKING SHORT-TERM DUAL ANTIPLATELET THERAPYS POTENTIAL: SAFETY AND EFFECTIVENESS IN LARGE ARTERY ATHEROSCLEROSIS INSIGHTS FROM THE READAPT STUDY Federico De Santis 1 , Eleonora De Matteis 1,2 , Matteo Foschi 1 , Michele Romoli 3 , Tiziana Tassinari 4 , Valentina Saia 4 , Silvia Cenciarelli 5 , Chiara Padiglioni 5 , Bruno Censori 6 , Luisa Vinciguerra 6 , Maria Guarino 7 , Marialuisa Zedde 8 , Marina Diomedi 9 , Marco Petruzzellis 10 , Danilo Toni 11 , Stefano Ricci 5 , Simona Sacco 1 , Raffaele Ornello 1 1 Department of Biotechnological and Applied Clinical Sciences, University of LAquila, LAquila, Italy, 2 Department of Brain Sciences, Imperial College London, London, United Kingdom, 3 Stroke Unit, Maurizio Bufalini Hospital, Cesena, Italy, 4 Department of Neurology, Santa Corona Hospital, Pietra Ligure, Italy, 5 Department of Neurology, Citt di Castello Hospital, Citt di Castello, Italy, 6 Department of Neurology, ASST Cremona Hospital, Cremona, Italy, 7 IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy, 8 Department of Neurology, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, 9 Department of Systems Medicine, Tor Vergata University Hospital, Rome, Italy, 10 Department of Neurology and Stroke Unit, F
(1999) Cell
Other improved services include new state-of-the-art operating rooms, private patient rooms, and standalone emergency departments for adults and children
SiRNA transient transfection was performed twice on consecutive days using 40 nM, non-targeting siRNA (si CTRL), siRNA against human ATG5 (si ATG5), ULK1 (si ULK1), ATG7 (si ATG7), and DRP1 (si DRP1) purchased from Dharmacon (D-001810, L-004374, L-005049, L-020112, and L-012092 respectively)
Carmen Garcia-Ruiz
